Charles Bankhead

News, features, and commentary about cancer-related issues

Sevabertinib produced a 71% response rate in patients without prior HER2-targeted therapy

Also at IKCS, potential marker for immunotherapy use, early promise for novel bispecific antibody

5-year mortality rate more than twice as high in patients not treated with the obesity drugs

Campaigns raised $506 million over 2 years, still just a fraction of out-of-pocket expenditures

Richard Pazdur has long history of streamlining drug and device approval process

The six drugs bring the total to 15 since mid-October

News, features, and commentary about cancer-related issues

MRD negativity will remain a prerequisite for cure and remain a hot topic for debate

News, features, and commentary about cancer-related issues

Effects of GLP-1 agonists, patient acceptance of geographic atrophy treatment, regulatory actions

No effect on metabolic syndrome but some impact on various components

Benefits dependent on completeness of surgery, absence of nodal involvement

News, features, and commentary about cancer-related issues

Age, type of treatment, and cardiac risk factors contributed the most to heart failure risk

Dato-DXd improves PFS, OS; sacituzumab govitecan boosts PFS in PD-(L)1-ineligible patients

EFS, OS improved by 50-60% with perioperative enfortumab vedotin plus pembrolizumab

News, features, and commentary about cancer-related issues

News, features, and commentary about cancer-related issues

Residents of rural, high-poverty areas derived greatest benefit versus non-expansion states